- 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
- 1.1 EXECUTIVE SUMMARY
- 1.1.1 Market Overview
- 1.1.2 Key Findings
- 1.1.3 Market Segmentation
- 1.1.4 Competitive Landscape
- 1.1.5 Challenges and Opportunities
- 1.1.6 Future Outlook
- 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
- 2.1 MARKET INTRODUCTION
- 2.1.1 Definition
- 2.1.2 Scope of the study
- 2.1.2.1 Research Objective
- 2.1.2.2 Assumption
- 2.1.2.3 Limitations
- 2.2 RESEARCH METHODOLOGY
- 2.2.1 Overview
- 2.2.2 Data Mining
- 2.2.3 Secondary Research
- 2.2.4 Primary Research
- 2.2.4.1 Primary Interviews and Information Gathering Process
- 2.2.4.2 Breakdown of Primary Respondents
- 2.2.5 Forecasting Model
- 2.2.6 Market Size Estimation
- 2.2.6.1 Bottom-Up Approach
- 2.2.6.2 Top-Down Approach
- 2.2.7 Data Triangulation
- 2.2.8 Validation
- 3 SECTION III: QUALITATIVE ANALYSIS
- 3.1 MARKET DYNAMICS
- 3.1.1 Overview
- 3.1.2 Drivers
- 3.1.3 Restraints
- 3.1.4 Opportunities
- 3.2 MARKET FACTOR ANALYSIS
- 3.2.1 Value chain Analysis
- 3.2.2 Porter's Five Forces Analysis
- 3.2.2.1 Bargaining Power of Suppliers
- 3.2.2.2 Bargaining Power of Buyers
- 3.2.2.3 Threat of New Entrants
- 3.2.2.4 Threat of Substitutes
- 3.2.2.5 Intensity of Rivalry
- 3.2.3 COVID-19 Impact Analysis
- 3.2.3.1 Market Impact Analysis
- 3.2.3.2 Regional Impact
- 3.2.3.3 Opportunity and Threat Analysis
- 4 SECTION IV: QUANTITATIVE ANALYSIS
- 4.1 Healthcare, BY Application (USD Billion)
- 4.1.1 Preventive Care
- 4.1.2 Post-Exposure Prophylaxis
- 4.1.3 Travel Health
- 4.1.4 Occupational Health
- 4.2 Healthcare, BY End Use (USD Billion)
- 4.2.1 Healthcare Providers
- 4.2.2 Pharmacies
- 4.2.3 Public Health Organizations
- 4.2.4 Corporate Health Programs
- 4.3 Healthcare, BY Age Group (USD Billion)
- 4.3.1 Pediatric
- 4.3.2 Adult
- 4.3.3 Geriatric
- 4.4 Healthcare, BY Vaccination Type (USD Billion)
- 4.4.1 Inactivated Vaccine
- 4.4.2 Live Attenuated Vaccine
- 4.4.3 Recombinant Vaccine
- 4.5 Healthcare, BY Region (USD Billion)
- 4.5.1 North America
- 4.5.1.1 US
- 4.5.1.2 Canada
- 4.5.2 Europe
- 4.5.2.1 Germany
- 4.5.2.2 UK
- 4.5.2.3 France
- 4.5.2.4 Russia
- 4.5.2.5 Italy
- 4.5.2.6 Spain
- 4.5.2.7 Rest of Europe
- 4.5.3 APAC
- 4.5.3.1 China
- 4.5.3.2 India
- 4.5.3.3 Japan
- 4.5.3.4 South Korea
- 4.5.3.5 Malaysia
- 4.5.3.6 Thailand
- 4.5.3.7 Indonesia
- 4.5.3.8 Rest of APAC
- 4.5.4 South America
- 4.5.4.1 Brazil
- 4.5.4.2 Mexico
- 4.5.4.3 Argentina
- 4.5.4.4 Rest of South America
- 4.5.5 MEA
- 4.5.5.1 GCC Countries
- 4.5.5.2 South Africa
- 4.5.5.3 Rest of MEA
- 5 SECTION V: COMPETITIVE ANALYSIS
- 5.1 Competitive Landscape
- 5.1.1 Overview
- 5.1.2 Competitive Analysis
- 5.1.3 Market share Analysis
- 5.1.4 Major Growth Strategy in the Healthcare
- 5.1.5 Competitive Benchmarking
- 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
- 5.1.7 Key developments and growth strategies
- 5.1.7.1 New Product Launch/Service Deployment
- 5.1.7.2 Merger & Acquisitions
- 5.1.7.3 Joint Ventures
- 5.1.8 Major Players Financial Matrix
- 5.1.8.1 Sales and Operating Income
- 5.1.8.2 Major Players R&D Expenditure. 2023
- 5.2 Company Profiles
- 5.2.1 Sanofi (FR)
- 5.2.1.1 Financial Overview
- 5.2.1.2 Products Offered
- 5.2.1.3 Key Developments
- 5.2.1.4 SWOT Analysis
- 5.2.1.5 Key Strategies
- 5.2.2 GlaxoSmithKline (GB)
- 5.2.2.1 Financial Overview
- 5.2.2.2 Products Offered
- 5.2.2.3 Key Developments
- 5.2.2.4 SWOT Analysis
- 5.2.2.5 Key Strategies
- 5.2.3 Pfizer (US)
- 5.2.3.1 Financial Overview
- 5.2.3.2 Products Offered
- 5.2.3.3 Key Developments
- 5.2.3.4 SWOT Analysis
- 5.2.3.5 Key Strategies
- 5.2.4 Merck & Co. (US)
- 5.2.4.1 Financial Overview
- 5.2.4.2 Products Offered
- 5.2.4.3 Key Developments
- 5.2.4.4 SWOT Analysis
- 5.2.4.5 Key Strategies
- 5.2.5 AstraZeneca (GB)
- 5.2.5.1 Financial Overview
- 5.2.5.2 Products Offered
- 5.2.5.3 Key Developments
- 5.2.5.4 SWOT Analysis
- 5.2.5.5 Key Strategies
- 5.2.6 Seqirus (AU)
- 5.2.6.1 Financial Overview
- 5.2.6.2 Products Offered
- 5.2.6.3 Key Developments
- 5.2.6.4 SWOT Analysis
- 5.2.6.5 Key Strategies
- 5.2.7 Baxter International (US)
- 5.2.7.1 Financial Overview
- 5.2.7.2 Products Offered
- 5.2.7.3 Key Developments
- 5.2.7.4 SWOT Analysis
- 5.2.7.5 Key Strategies
- 5.2.8 Novartis (CH)
- 5.2.8.1 Financial Overview
- 5.2.8.2 Products Offered
- 5.2.8.3 Key Developments
- 5.2.8.4 SWOT Analysis
- 5.2.8.5 Key Strategies
- 5.2.9 MedImmune (GB)
- 5.2.9.1 Financial Overview
- 5.2.9.2 Products Offered
- 5.2.9.3 Key Developments
- 5.2.9.4 SWOT Analysis
- 5.2.9.5 Key Strategies
- 5.3 Appendix
- 5.3.1 References
- 5.3.2 Related Reports
- 6 LIST OF FIGURES
- 6.1 MARKET SYNOPSIS
- 6.2 NORTH AMERICA MARKET ANALYSIS
- 6.3 US MARKET ANALYSIS BY APPLICATION
- 6.4 US MARKET ANALYSIS BY END USE
- 6.5 US MARKET ANALYSIS BY AGE GROUP
- 6.6 US MARKET ANALYSIS BY VACCINATION TYPE
- 6.7 CANADA MARKET ANALYSIS BY APPLICATION
- 6.8 CANADA MARKET ANALYSIS BY END USE
- 6.9 CANADA MARKET ANALYSIS BY AGE GROUP
- 6.10 CANADA MARKET ANALYSIS BY VACCINATION TYPE
- 6.11 EUROPE MARKET ANALYSIS
- 6.12 GERMANY MARKET ANALYSIS BY APPLICATION
- 6.13 GERMANY MARKET ANALYSIS BY END USE
- 6.14 GERMANY MARKET ANALYSIS BY AGE GROUP
- 6.15 GERMANY MARKET ANALYSIS BY VACCINATION TYPE
- 6.16 UK MARKET ANALYSIS BY APPLICATION
- 6.17 UK MARKET ANALYSIS BY END USE
- 6.18 UK MARKET ANALYSIS BY AGE GROUP
- 6.19 UK MARKET ANALYSIS BY VACCINATION TYPE
- 6.20 FRANCE MARKET ANALYSIS BY APPLICATION
- 6.21 FRANCE MARKET ANALYSIS BY END USE
- 6.22 FRANCE MARKET ANALYSIS BY AGE GROUP
- 6.23 FRANCE MARKET ANALYSIS BY VACCINATION TYPE
- 6.24 RUSSIA MARKET ANALYSIS BY APPLICATION
- 6.25 RUSSIA MARKET ANALYSIS BY END USE
- 6.26 RUSSIA MARKET ANALYSIS BY AGE GROUP
- 6.27 RUSSIA MARKET ANALYSIS BY VACCINATION TYPE
- 6.28 ITALY MARKET ANALYSIS BY APPLICATION
- 6.29 ITALY MARKET ANALYSIS BY END USE
- 6.30 ITALY MARKET ANALYSIS BY AGE GROUP
- 6.31 ITALY MARKET ANALYSIS BY VACCINATION TYPE
- 6.32 SPAIN MARKET ANALYSIS BY APPLICATION
- 6.33 SPAIN MARKET ANALYSIS BY END USE
- 6.34 SPAIN MARKET ANALYSIS BY AGE GROUP
- 6.35 SPAIN MARKET ANALYSIS BY VACCINATION TYPE
- 6.36 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
- 6.37 REST OF EUROPE MARKET ANALYSIS BY END USE
- 6.38 REST OF EUROPE MARKET ANALYSIS BY AGE GROUP
- 6.39 REST OF EUROPE MARKET ANALYSIS BY VACCINATION TYPE
- 6.40 APAC MARKET ANALYSIS
- 6.41 CHINA MARKET ANALYSIS BY APPLICATION
- 6.42 CHINA MARKET ANALYSIS BY END USE
- 6.43 CHINA MARKET ANALYSIS BY AGE GROUP
- 6.44 CHINA MARKET ANALYSIS BY VACCINATION TYPE
- 6.45 INDIA MARKET ANALYSIS BY APPLICATION
- 6.46 INDIA MARKET ANALYSIS BY END USE
- 6.47 INDIA MARKET ANALYSIS BY AGE GROUP
- 6.48 INDIA MARKET ANALYSIS BY VACCINATION TYPE
- 6.49 JAPAN MARKET ANALYSIS BY APPLICATION
- 6.50 JAPAN MARKET ANALYSIS BY END USE
- 6.51 JAPAN MARKET ANALYSIS BY AGE GROUP
- 6.52 JAPAN MARKET ANALYSIS BY VACCINATION TYPE
- 6.53 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
- 6.54 SOUTH KOREA MARKET ANALYSIS BY END USE
- 6.55 SOUTH KOREA MARKET ANALYSIS BY AGE GROUP
- 6.56 SOUTH KOREA MARKET ANALYSIS BY VACCINATION TYPE
- 6.57 MALAYSIA MARKET ANALYSIS BY APPLICATION
- 6.58 MALAYSIA MARKET ANALYSIS BY END USE
- 6.59 MALAYSIA MARKET ANALYSIS BY AGE GROUP
- 6.60 MALAYSIA MARKET ANALYSIS BY VACCINATION TYPE
- 6.61 THAILAND MARKET ANALYSIS BY APPLICATION
- 6.62 THAILAND MARKET ANALYSIS BY END USE
- 6.63 THAILAND MARKET ANALYSIS BY AGE GROUP
- 6.64 THAILAND MARKET ANALYSIS BY VACCINATION TYPE
- 6.65 INDONESIA MARKET ANALYSIS BY APPLICATION
- 6.66 INDONESIA MARKET ANALYSIS BY END USE
- 6.67 INDONESIA MARKET ANALYSIS BY AGE GROUP
- 6.68 INDONESIA MARKET ANALYSIS BY VACCINATION TYPE
- 6.69 REST OF APAC MARKET ANALYSIS BY APPLICATION
- 6.70 REST OF APAC MARKET ANALYSIS BY END USE
- 6.71 REST OF APAC MARKET ANALYSIS BY AGE GROUP
- 6.72 REST OF APAC MARKET ANALYSIS BY VACCINATION TYPE
- 6.73 SOUTH AMERICA MARKET ANALYSIS
- 6.74 BRAZIL MARKET ANALYSIS BY APPLICATION
- 6.75 BRAZIL MARKET ANALYSIS BY END USE
- 6.76 BRAZIL MARKET ANALYSIS BY AGE GROUP
- 6.77 BRAZIL MARKET ANALYSIS BY VACCINATION TYPE
- 6.78 MEXICO MARKET ANALYSIS BY APPLICATION
- 6.79 MEXICO MARKET ANALYSIS BY END USE
- 6.80 MEXICO MARKET ANALYSIS BY AGE GROUP
- 6.81 MEXICO MARKET ANALYSIS BY VACCINATION TYPE
- 6.82 ARGENTINA MARKET ANALYSIS BY APPLICATION
- 6.83 ARGENTINA MARKET ANALYSIS BY END USE
- 6.84 ARGENTINA MARKET ANALYSIS BY AGE GROUP
- 6.85 ARGENTINA MARKET ANALYSIS BY VACCINATION TYPE
- 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
- 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE
- 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY AGE GROUP
- 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY VACCINATION TYPE
- 6.90 MEA MARKET ANALYSIS
- 6.91 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
- 6.92 GCC COUNTRIES MARKET ANALYSIS BY END USE
- 6.93 GCC COUNTRIES MARKET ANALYSIS BY AGE GROUP
- 6.94 GCC COUNTRIES MARKET ANALYSIS BY VACCINATION TYPE
- 6.95 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
- 6.96 SOUTH AFRICA MARKET ANALYSIS BY END USE
- 6.97 SOUTH AFRICA MARKET ANALYSIS BY AGE GROUP
- 6.98 SOUTH AFRICA MARKET ANALYSIS BY VACCINATION TYPE
- 6.99 REST OF MEA MARKET ANALYSIS BY APPLICATION
- 6.100 REST OF MEA MARKET ANALYSIS BY END USE
- 6.101 REST OF MEA MARKET ANALYSIS BY AGE GROUP
- 6.102 REST OF MEA MARKET ANALYSIS BY VACCINATION TYPE
- 6.103 KEY BUYING CRITERIA OF HEALTHCARE
- 6.104 RESEARCH PROCESS OF MRFR
- 6.105 DRO ANALYSIS OF HEALTHCARE
- 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
- 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
- 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
- 6.109 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
- 6.110 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
- 6.111 HEALTHCARE, BY END USE, 2024 (% SHARE)
- 6.112 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
- 6.113 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
- 6.114 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Billion)
- 6.115 HEALTHCARE, BY VACCINATION TYPE, 2024 (% SHARE)
- 6.116 HEALTHCARE, BY VACCINATION TYPE, 2024 TO 2035 (USD Billion)
- 6.117 BENCHMARKING OF MAJOR COMPETITORS
- 7 LIST OF TABLES
- 7.1 LIST OF ASSUMPTIONS
- 7.1.1
- 7.2 North America MARKET SIZE ESTIMATES; FORECAST
- 7.2.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.2.2 BY END USE, 2025-2035 (USD Billion)
- 7.2.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.2.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.3 US MARKET SIZE ESTIMATES; FORECAST
- 7.3.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.3.2 BY END USE, 2025-2035 (USD Billion)
- 7.3.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.3.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
- 7.4.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.4.2 BY END USE, 2025-2035 (USD Billion)
- 7.4.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.4.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
- 7.5.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.5.2 BY END USE, 2025-2035 (USD Billion)
- 7.5.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.5.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
- 7.6.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.6.2 BY END USE, 2025-2035 (USD Billion)
- 7.6.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.6.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.7 UK MARKET SIZE ESTIMATES; FORECAST
- 7.7.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.7.2 BY END USE, 2025-2035 (USD Billion)
- 7.7.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.7.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.8 France MARKET SIZE ESTIMATES; FORECAST
- 7.8.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.8.2 BY END USE, 2025-2035 (USD Billion)
- 7.8.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.8.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
- 7.9.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.9.2 BY END USE, 2025-2035 (USD Billion)
- 7.9.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.9.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
- 7.10.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.10.2 BY END USE, 2025-2035 (USD Billion)
- 7.10.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.10.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
- 7.11.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.11.2 BY END USE, 2025-2035 (USD Billion)
- 7.11.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.11.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
- 7.12.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.12.2 BY END USE, 2025-2035 (USD Billion)
- 7.12.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.12.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
- 7.13.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.13.2 BY END USE, 2025-2035 (USD Billion)
- 7.13.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.13.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.14 China MARKET SIZE ESTIMATES; FORECAST
- 7.14.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.14.2 BY END USE, 2025-2035 (USD Billion)
- 7.14.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.14.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.15 India MARKET SIZE ESTIMATES; FORECAST
- 7.15.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.15.2 BY END USE, 2025-2035 (USD Billion)
- 7.15.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.15.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
- 7.16.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.16.2 BY END USE, 2025-2035 (USD Billion)
- 7.16.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.16.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
- 7.17.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.17.2 BY END USE, 2025-2035 (USD Billion)
- 7.17.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.17.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
- 7.18.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.18.2 BY END USE, 2025-2035 (USD Billion)
- 7.18.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.18.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
- 7.19.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.19.2 BY END USE, 2025-2035 (USD Billion)
- 7.19.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.19.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
- 7.20.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.20.2 BY END USE, 2025-2035 (USD Billion)
- 7.20.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.20.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
- 7.21.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.21.2 BY END USE, 2025-2035 (USD Billion)
- 7.21.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.21.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.22 South America MARKET SIZE ESTIMATES; FORECAST
- 7.22.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.22.2 BY END USE, 2025-2035 (USD Billion)
- 7.22.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.22.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
- 7.23.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.23.2 BY END USE, 2025-2035 (USD Billion)
- 7.23.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.23.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
- 7.24.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.24.2 BY END USE, 2025-2035 (USD Billion)
- 7.24.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.24.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
- 7.25.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.25.2 BY END USE, 2025-2035 (USD Billion)
- 7.25.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.25.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
- 7.26.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.26.2 BY END USE, 2025-2035 (USD Billion)
- 7.26.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.26.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
- 7.27.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.27.2 BY END USE, 2025-2035 (USD Billion)
- 7.27.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.27.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
- 7.28.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.28.2 BY END USE, 2025-2035 (USD Billion)
- 7.28.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.28.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
- 7.29.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.29.2 BY END USE, 2025-2035 (USD Billion)
- 7.29.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.29.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
- 7.30.1 BY APPLICATION, 2025-2035 (USD Billion)
- 7.30.2 BY END USE, 2025-2035 (USD Billion)
- 7.30.3 BY AGE GROUP, 2025-2035 (USD Billion)
- 7.30.4 BY VACCINATION TYPE, 2025-2035 (USD Billion)
- 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
- 7.31.1
- 7.32 ACQUISITION/PARTNERSHIP
- 7.32.1
Customer Stories
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
“Thank you, this will be very helpful for OQS.”
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”